BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34083693)

  • 1. BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4.
    Choi HI; An GY; Baek M; Yoo E; Chai JC; Lee YS; Jung KH; Chai YG
    Sci Rep; 2021 Jun; 11(1):11799. PubMed ID: 34083693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMARCA4 (BRG1) activates ABCC3 transcription to promote hepatocellular carcinogenesis.
    Liu H; Yue L; Hong W; Zhou J
    Life Sci; 2024 Jun; 347():122605. PubMed ID: 38642845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of miR-329 promotes cell invasion by regulating BRD4 and predicts poor prognosis in hepatocellular carcinoma.
    Zhou J; Li W; Guo J; Li G; Chen F; Zhou J
    Tumour Biol; 2016 Mar; 37(3):3561-9. PubMed ID: 26456956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA-608 inhibits human hepatocellular carcinoma cell proliferation via targeting the BET family protein BRD4.
    He L; Meng D; Zhang SH; Zhang Y; Deng Z; Kong LB
    Biochem Biophys Res Commun; 2018 Jul; 501(4):1060-1067. PubMed ID: 29777702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma.
    Endo M; Yasui K; Zen Y; Gen Y; Zen K; Tsuji K; Dohi O; Mitsuyoshi H; Tanaka S; Taniwaki M; Nakanuma Y; Arii S; Yoshikawa T
    Liver Int; 2013 Jan; 33(1):105-17. PubMed ID: 23088494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET inhibitor suppresses melanoma progression
    Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
    Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
    [No Abstract]   [Full Text] [Related]  

  • 8. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Zhang P; Dong Z; Cai J; Zhang C; Shen Z; Ke A; Gao D; Fan J; Shi G
    Int J Immunopathol Pharmacol; 2015 Mar; 28(1):36-44. PubMed ID: 25816404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
    Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
    J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANP32A promotes the proliferation, migration and invasion of hepatocellular carcinoma by modulating the HMGA1/STAT3 pathway.
    Tian Z; Liu Z; Fang X; Cao K; Zhang B; Wu R; Wen X; Wen Q; Shi H; Wang R
    Carcinogenesis; 2021 Apr; 42(3):493-506. PubMed ID: 33332531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma.
    Lu SX; Zhang CZ; Luo RZ; Wang CH; Liu LL; Fu J; Zhang L; Wang H; Xie D; Yun JP
    Cancer Lett; 2017 Aug; 402():71-80. PubMed ID: 28577975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Mybbp1a suppresses HCC progression via inhibiting IGF1/AKT pathway by CpG islands hypo-methylation dependent promotion of IGFBP5.
    Weng X; Wu J; Lv Z; Peng C; Chen J; Zhang C; He B; Tong R; Hu W; Ding C; Cao L; Chen D; Wu J; Zheng S
    EBioMedicine; 2019 Jun; 44():225-236. PubMed ID: 31109829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PES1 is transcriptionally regulated by BRD4 and promotes cell proliferation and glycolysis in hepatocellular carcinoma.
    Fan P; Wang B; Meng Z; Zhao J; Jin X
    Int J Biochem Cell Biol; 2018 Nov; 104():1-8. PubMed ID: 30172011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogene-dependent function of BRG1 in hepatocarcinogenesis.
    Wang P; Song X; Cao D; Cui K; Wang J; Utpatel K; Shang R; Wang H; Che L; Evert M; Zhao K; Calvisi DF; Chen X
    Cell Death Dis; 2020 Feb; 11(2):91. PubMed ID: 32019910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms.
    Xiao Y; Najeeb RM; Ma D; Yang K; Zhong Q; Liu Q
    J Exp Clin Cancer Res; 2019 Nov; 38(1):458. PubMed ID: 31703591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRG1 promotes hepatocarcinogenesis by regulating proliferation and invasiveness.
    Kaufmann B; Wang B; Zhong S; Laschinger M; Patil P; Lu M; Assfalg V; Cheng Z; Friess H; Hüser N; von Figura G; Hartmann D
    PLoS One; 2017; 12(7):e0180225. PubMed ID: 28700662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear expression of the ubiquitin ligase seven in absentia homolog (SIAH)-1 induces proliferation and migration of liver cancer cells.
    Brauckhoff A; Malz M; Tschaharganeh D; Malek N; Weber A; Riener MO; Soll C; Samarin J; Bissinger M; Schmidt J; Longerich T; Ehemann V; Schirmacher P; Breuhahn K
    J Hepatol; 2011 Nov; 55(5):1049-57. PubMed ID: 21356256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.